Indian government is working actively to stop black marketing of medicines in the future

  • News
  • June 16, 2017

New Delhi : National Pharmaceutical Pricing Authority (NPPA) has taken one step forward and fixed ceiling price (CP) of 1 scheduled formulation and Maximum Retail Price (MRP) of 4 formulations to stop black marketing.

NPPA revised prices under Drugs (Price Control) Amendment Order, 2016 (under DPCO, 2013) and retail prices of 4 formulations under DPCO, 2013. Clotrimazol’s ceiling price is fixed now and NPPA officials also added that the manufacturers of scheduled formulations, selling the branded / generic / both versions of scheduled formulations at a price higher than the ceiling price [plus local taxes as applicable] fixed and notified by the government, shall revise the prices.

Retail Price of four medicines Pacimol 10mg/ml Infusion, Pacimol MF tablet, Ten- DC M 500 tablet and Ten – DC M 1000 tablet MRP has been fixed under DPCO, 2013. Officials said we are now covering common medicines and started with major drugs and products like stents. The allowed price change is in the range of 10% to 15% only.  We are ensuring this step will definitely curb black marketing and benefits consumers.

To help consumers to aware them about the price change, retailers expected to show main and supplementary list if any, as furnished by the manufacturer. Deposits should be made with an interest in the case of overcharging under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.

NPPA notified all manufacturers to maintain MRP in case if it is lower than capped price. Pharma manufacturers permitted to add local taxes if they have paid them or if it is payable to the government on the ceiling price mentioned.

  • Related Posts

    • News
    • May 27, 2025
    • 239 views
    Ramping Up Community for JeevanRaksha during Disasters

    CBDM India 2025 will Champion Health Resilience and Local Response Bengaluru: As India and its neighbours continue to confront the double threat of increasing natural disasters and unpredictable man-made crises—including…

    • News
    • February 1, 2025
    • 356 views
    Union Budget 2025 pleased Healthcare Leaders except for a Letdown or two

    New Delhi: Healthcare leaders expressed overall satisfaction over Union Budget 2025 except for a letdown or two. Rajiv Nath, Forum Coordinator, Association of Indian Medical Device Industry (AiMeD), though appreciated…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Novo Nordisk launches blockbuster weight-loss drug Wegovy in India; Check price, dosage and other details

    Novo Nordisk launches blockbuster weight-loss drug Wegovy in India; Check price, dosage and other details

    Aurobindo Pharma arm gets marketing authorization in UK for Dyrupeg

    Aurobindo Pharma arm gets marketing authorization in UK for Dyrupeg

    Sun Pharma’s European partner withdraws application for skin cancer treatment therapy

    Sun Pharma’s European partner withdraws application for skin cancer treatment therapy

    Glenmark Pharma launches TEVIMBRA in India

    Glenmark Pharma launches TEVIMBRA in India